Jump to content

Lysosome

From Wikipedia, the free encyclopedia
(Redirected from Lysozome)
Not to be confused with Lysozyme or lectins.

Cell biology
Animal cell diagram
Components of a typical animal cell:
  1. Nucleolus
  2. Nucleus
  3. Ribosome (dots as part of 5)
  4. Vesicle
  5. Rough endoplasmic reticulum
  6. Golgi apparatus (or, Golgi body)
  7. Cytoskeleton
  8. Smooth endoplasmic reticulum
  9. Mitochondrion
  10. Vacuole
  11. Cytosol (fluid that contains organelles; with which, comprises cytoplasm)
  12. Lysosome
  13. Centrosome
  14. Cell membrane

A lysosome (/ˈlaɪsəˌsoʊm/) is a membrane-bound organelle that is found in all mammalian cells, with the exception of red blood cells (erythrocytes).[1] There are normally hundreds of lysosomes in the cytosol, where they function as the cell’s degradation center. Their primary responsibility is catabolic degradation of proteins, polysaccharides and lipids into their respective building-block molecules: amino acids, monosaccharides, and free fatty acids. The breakdown is done by various enzymes, for example proteases, glycosidases and lipases.[2]

With an acidic lumen limited by a single-bilayer lipid membrane, the lysosome holds an environment isolated from the rest of the cell. The lower pH creates optimal conditions for the over 60 different hydrolases inside.[3]

Lysosomes receive extracellular particles through endocytosis, and intracellular components through autophagy.[2] They can also fuse with the plasma membrane and secrete their contents, a process called lysosomal exocytosis.[3] After degradation lysosomal products are transported out of the lysosome through specific membrane proteins or via vesicular membrane trafficking to be recycled or to be utilized for energy.[2]

Aside from cellular clearance and secretion, lysosomes mediate biological processes like plasma membrane repair, cell homeostasis, energy metabolism, cell signaling, and the immune response.[3]

Discovery

[edit]
Christian de Duve, age 95, presenting his ideas on the origin of the eukaryotic cell (October 2012)

Christian de Duve, a Belgian scientist at the Laboratory of Physiological Chemistry at the Catholic University of Louvain, is credited with discovering lysosomes in the 1950s. De Duve and his team were studying the distribution of hydrolytic enzymes such as acid phosphatase within cells, using cell fractionation methods to isolate subcellular components. De Duve and his team identified an unknown organelle that was rich in acid phosphatase. This led them to propose the existence of lysosomes as membrane bound organelles containing digestive enzymes capable of breaking down a variety of biological molecules.

Using differential centrifugation and enzyme activity assays, the team confirmed the hypothesis and understood that these organelles play a crucial role in intracellular digestion processes, such as phagocytosis and autophagy. The presence of digestive enzymes was further validated using electron microscopy. De Duve’s discovery laid the foundation for new research into lysosomal functions and understanding disorders which could lead to undigested materials accumulating in the cell. De Duve was awarded the Nobel Prize in Physiology or Medicine in 1974.[4][5]

Function and structure

[edit]
TEM views of various vesicular compartments. Lysosomes are denoted by "Ly". They are dyed dark due to their acidity; in the center of the top image, a Golgi Apparatus can be seen, distal from the cell membrane relative to the lysosome.

Lysosomes vary in shape and size depending on their state, what they are digesting, and the cell type they are in.[6] Their shape can differ from spherical and ovoid to occasionally tubular.[7] The size of lysosomes ranges from 0.1-1.2 μm[6], with some tubular ones reaching up to 15 μm in phagocytes. Several hundred lysosomes can be found within a single cell. However, upon nutrient deprivation or induced autophagy, their numbers can drop below 50 in a cell.[8]

Lysosomes contain a variety of enzymes that enable the cell to break down various biomolecules it engulfs, including peptides, nucleic acids, carbohydrates, and lipids. The enzymes responsible for this hydrolysis require an acidic environment for optimal activity, with a pH ranging from ~4.5–5.0. The interior of the lysosome is acidic compared to the slightly basic cytosol (pH 7.2).[9]

The lysosomal membrane is a phospholipid bilayer with high carbohydrate content from heavily glycosylated membrane proteins. This forms a glycocalyx that protects the cell from the degradative enzymes held within the lysosome. Lysosomal hydrolases are pH-sensitive and do not function properly in the alkaline environment of the cytosol, ensuring that molecules and organelles in the cytosol are not degraded if there is leakage of hydrolytic enzymes from the lysosome.

In addition to breaking down polymers, lysosomes are capable of killing and digesting microbes, cells, or cellular debris. Through cooperation with phagosomes, lysosomes conduct autophagy, clearing out damaged structures and forming simple compounds, which are then used as new building materials. Similarly, lysosomes break down virus particles or bacteria during phagocytosis in macrophages.[10][11]

Lysosomes also help detect pathogens through toll-like receptors (TLRs), like TLR7 and TLR9. Microbes can be degraded into antigens, which are then loaded onto MHC molecules and presented to T-cells, a critical part of immune defense. Additionally, lysosomal enzymes can trigger lysosomal-mediated programmed cell death (LM-PCD) if released into the cytoplasm.

To maintain their acidic environment, lysosomes pump protons (H⁺ ions) from the cytosol into the lysosomal lumen via a proton pump in the lysosomal membrane. Vacuolar-ATPases are responsible for the transport of protons, while the counter transport of chloride ions is performed by ClC-7 Cl⁻/H⁺ antiporter.[12] This mechanism helps maintain a steady acidic environment, as well as ionic homeostasis, within the lysosome.[13][14]

Lysosomes also help balance cellular metabolism by sensing nutrient availability. When nutrients are plentiful, they activate mTOR signaling to support anabolic (biosynthetic) processes. During starvation, lysosomes degrade autophagic material, recycling components to maintain cell survival.

Lysosomal degradation pathways

[edit]
Cellular material is delivered to lysosomes in four different ways; (A) Macroautophagy, (B) Endosomal degradation, (C) Microautophagy and (D) Chaperone-mediated autophagy (CMA).

The lysosome is delivered material for degradation via transient interactions or complete fusion, forming endolysosomes and autolysosomes respectively. This way, the lysosomes act as reservoirs for acidic hydrolases, cycling through fusion and fission events with late endosomes and autophagosomes. The actual breakdown of endocytic and autophagic cargo primarily happens within these transient structures—endolysosomes and autolysosomes—under normal physiological conditions.[15]

Endocytosed materials – such as complex lipids, membrane proteins, and polysaccharides – enter the endocytic pathway; moving first in early endosomes, then in late endosomes containing intraluminal vesicles (also referred to as multivesicular bodies, MVBs). Then they interact with lysosomes, either via full fusion, or via "kiss-and-run" events where brief membrane contact allows content exchange before the organelles separate. The resulting hybrid structure is called an endolysosome.[16][15]

Intracellular materials – like damaged organelles or misfolded proteins – are processed through the autophagic pathway.[16] Autophagy, or “self-eating,” is a continuous cellular process that delivers cytosolic components to lysosomes for degradation. There are three main types of autophagy: macroautophagy, microautophagy, and chaperone-mediated autophagy (CMA)—each differing in how cargo is delivered to the lysosome.[15] After merging with lysosomes they create hybrid organelles called autolysosomes.[16]

  • Macroautophagy involves the formation of isolated double- or multi-membranes that encapsulate portions of cytosolic material such as misfolded- or polyubiquitinated proteins, lipids, damaged or aged organelles, RNA, and fragments of the ER. These vesicles mature into autophagosomes and then fuse with lysosomes for degradation, creating an autolysosome. A key marker of autophagosomes is LC3-II, a lipidated form of microtubule-associated protein light chain 3 (MAP-LC3) that appears early in the process and is broken down during digestion
  • Microautophagy bypasses vesicle formation altogether, with lysosomes directly engulfing surrounding cytosolic material through membrane invagination; pinocytosis. This process is similar to the formation of intraluminal vesicles in MVBs.
  • Chaperone-mediated autophagy (CMA) selectively degrades proteins that contain a KFERQ motif. These substrates are recognized by Hsc70, which binds them and delivers them to lysosomes via the receptor LAMP-2A for degradation.[15]


The resulting catabolites serve as building-block molecules for synthesizing complex macromolecules. These are exported from lysosomes via specific transporters or through vesicle trafficking. Once released into the cytosol or delivered to the Golgi apparatus, these catabolites are either further metabolized to generate energy or reused in biosynthetic pathways to form new complex molecules. Alternatively, some degradation products can be secreted out of the lysosomes through exocytosis.[16]

Because catabolic (degradative) and anabolic (biosynthetic) pathways are interconnected and tightly regulated, the flow of cargo through the endocytic and autophagic systems is modulated by cellular signaling and nutrient availability. Nutrient deprivation, for example, activates autophagy, which is then halted once lysosomal degradation is complete. Lysosomes themselves play a direct role in sensing nutrient levels through the lysosomal nutrient-sensing (LYNUS) system, which includes components such as V-ATPase, Rag GTPases, and the mTOR complex.[16]

Formation

[edit]
Process of phagocytosis: 1. A particle is ingested by a phagocyte after antigens are recognized which results in the formation of a phagosome. 2. The fusion of lysosomes with the phagosome creates a phagolysosome. The particle is broken down by the digestive enzymes found in the lysosomes.

The formation of lysosomes begins in the endoplasmic reticulum, where hydrolytic enzymes are synthesized. These enzymes are then transported to the Golgi apparatus (Golgi body), where they undergo modifications to ensure proper targeting and function. The enzymes are tagged with mannose-6-phosphate[17], allowing them to be sorted into vesicles. These vesicles then bud off from the trans-Golgi network and fuse with early endosomes.[18][19]

Early endosomes degrade cargo from the extracellular environment, and as they mature into late endosomes, proton pumps are activated, causing the internal environment to become acidic. This acidic environment activates the hydrolytic enzymes, which further mature the endosome into a lysosome.[20] The lysosome then breaks down and recycles cellular waste.[21]

Disruptions in lysosomal formation can lead to dysfunctional lysosomes and the accumulation of undigested molecules, contributing to various lysosomal storage disorders.[22]

Pathogen entry

[edit]

Lysosomes play a crucial role in defending the cell against pathogens such as viruses or bacteria. When a pathogen enters the cell, it is often enclosed in a phagosome which then fuses with a lysosome to form a phagolysosome where the hydrolytic enzymes break down the pathogen.[23][24] Lysosomes are a crucial part of innate immune system.[25] Lysosomes also play a big role in adaptive immune system where fragments of pathogens that are broken down by phagolysosomes are sent to the major histocompatibility complex class II (MHC II) and presented on the surface of antigen presenting cells (APCs). Which then activates helper T cells and then causes an adaptive immune response.[26][27]

When viruses enter the cell via endocytosis, they get degraded in lysosomes but then some viruses have evolved strategies to escape lysosomes. During degradation of viruses in the lysosome, the virus can escape the lysosome before complete degradation and spreading viral material into the cytoplasm which then spreads viral infection in the cell. So, lysosomes need to effectively degrade all the biomolecules, in other words, poor lysosomal activity results in higher viral infections by viruses such as HIV.[28][29]

Clinical significance

[edit]

Lysosomal storage disorders are a group of metabolic disorders that stem from inherited genetic mutations that disrupt normal lysosomal function and homeostasis.[30][31] Most frequently, the mutations are located in the acidic hydrolases but can also be found in non-enzymatic lysosomal proteins (soluble and membrane-bound) and non-lysosomal factors controlling lysosomal function.[32] This leads to defective degradation, and therefore induces abnormal accumulations of un- or partially digested macromolecules within lysosomes. Lysosomal dysfunction also affect transport across the lysosomal membrane, vesicle trafficking, lysosome reformation and autophagy.[33][34]

The stress of accumulated lysosomal substrates can lead to lysosomal membrane permeabilization, allowing hydrolytic enzymes to leak into the cytosol and initiate cell death. This cell loss particularly affects post-mitotic tissues such as the brain, liver, eyes, muscles, and spleen—resulting in the hallmark symptoms of lysosomal storage disorders, including neurodegeneration, cognitive impairment, and motor dysfunction. [31][35]

The age of onset and the specific symptoms in lysosomal storage disorders differ depending on the severity of the mutations, the cell types affected and what substrates accumulate. However, the clinical presentation is typically a neurodegenerative disease at childhood, with more variations presenting themselves in adulthood. In most cases, the central nervous system (CNS) is affected, causing the brain to experience global neurodegeneration, inflammation, activation of the innate immune system and astrogliosis.[31]

Several therapeutic strategies have been developed to address lysosomal storage disorders. These include substrate reduction therapy, bone marrow transplantation, gene therapy, and enzyme replacement therapy. Currently, enzyme replacement therapy and substrate reduction are the most widely used. However, despite these advancements most lysosomal storage disorders still lack effective treatments as the existing ones often are limited by poor efficacy and are typically disease specific.[31]

Lysosomotropism

[edit]

Lysosomotropism refers to the tendency of lipophilic weak bases to accumulate in acidic organelles like lysosomes. While neutral forms of these compounds cross membranes easily, their protonated (charged) forms become trapped inside lysosomes, leading to concentrations up to 1000 times higher than outside the cell.[36][37] This “acid trapping” or “proton pump” effect can be predicted using mathematical models.[38]

Many approved drugs, including haloperidol[39], levomepromazine[40], and amantadine,[41] exhibit lysosomotropic behavior. This helps explain their high tissue-to-blood concentration ratios and prolonged tissue retention, though fat solubility also contributes.

Some lysosomotropic drugs can interfere with lysosomal enzymes like acid sphingomyelinase.[42][43] Ambroxol, a mucolytic, promotes lysosomal exocytosis by neutralizing lysosomal pH and releasing stored calcium.[44] This action may underlie its observed benefits in diseases linked to lysosomal dysfunction, including Parkinson's disease and lysosomal storage disorders.[45][46]

Systemic lupus erythematosus (Lupus)

[edit]

Systemic lupus erythematosus (SLE) otherwise known as Lupus is an autoimmune disease where the immune system attacks healthy cells.[47] Lupus is prominent in systemic lupus erythematosus preventing macrophages and monocytes from degrading neutrophil extracellular traps[48] and immune complexes.[49][50][51] The failure to degrade internalized immune complexes rises from irregularly extended activity of mTORC2, which impairs lysosome acidification.[52] As a result, immune complexes in the lysosome recycle to the surface of macrophages causing an accumulation of DNA fragments and nuclear complexes which triggers an immune response from the body which is leads to the multiple lupus-associated pathologies.[49][53][54]

Different types of enzymes present in lysosomes

[edit]

There are over 50 different types of hydrolytic enzymes in lysosomes, the table below shows a few of the main types and their substrates. It is important to keep in mind that each category below has multiple different types of enzymes.

Sr. No Enzymes Substrate
1 Proteases Proteins and Peptides (breaks peptide bonds)[55]
2 Nucleases DNA and RNA (cleaves phosphodiester bonds)[56]
3 Glycosidases Carbohydrates (breaks glycosidic bonds)[57]
4 Lipases Lipids (breaks ester bonds)[58]
5 Phospholipases Phospholipids (cleaves fatty acids from phospholipids)[59]
7 Phosphatases Phosphorylated molecules (removes phosphate groups)[60]
8 Sulfatases Sulfated molecules (removes sulphate groups)[61]

See also

[edit]

References

[edit]
  1. ^ Saftig, Paul (20 March 2007). Lysosomes. Springer Science & Business Media. ISBN 978-0-387-28957-1.
  2. ^ a b c Xu, Haoxing; Ren, Dejian (10 February 2015). "Lysosomal Physiology". Annual Review of Physiology. 77: 57–80. doi:10.1146/annurev-physiol-021014-071649. ISSN 0066-4278. PMC 4524569. PMID 25668017.
  3. ^ a b c Settembre, Carmine; Fraldi, Alessandro; Medina, Diego L.; Ballabio, Andrea (May 2013). "Signals from the lysosome: a control centre for cellular clearance and energy metabolism". Nature Reviews. Molecular Cell Biology. 14 (5): 283–296. doi:10.1038/nrm3565. ISSN 1471-0080. PMC 4387238. PMID 23609508.
  4. ^ Sabatini, David D.; Adesnik, Milton (13 August 2013). "Christian de Duve: Explorer of the cell who discovered new organelles by using a centrifuge". Proceedings of the National Academy of Sciences of the United States of America. 110 (33): 13234–13235. doi:10.1073/pnas.1312084110. ISSN 1091-6490. PMC 3746853. PMID 23924611.
  5. ^ Cooper, Geoffrey M. (2000), "Lysosomes", The Cell: A Molecular Approach. 2nd edition, Sinauer Associates, retrieved 9 April 2025
  6. ^ a b Kühnel, Wolfgang; Kühnel, Wolfgang (2003). Color atlas of cytology, histology, and microscopic anatomy. Thieme Flexibook Basic sciences (4. ed., rev. and enl ed.). Stuttgart New York: Thieme. ISBN 978-1-58890-175-0.
  7. ^ Bouhamdani, Nadia; Comeau, Dominique; Turcotte, Sandra (15 December 2021). "A Compendium of Information on the Lysosome". Frontiers in Cell and Developmental Biology. 9. doi:10.3389/fcell.2021.798262. ISSN 2296-634X. PMC 8714965. PMID 34977038.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  8. ^ Bouhamdani, Nadia; Comeau, Dominique; Turcotte, Sandra (15 December 2021). "A Compendium of Information on the Lysosome". Frontiers in Cell and Developmental Biology. 9. doi:10.3389/fcell.2021.798262. ISSN 2296-634X. PMC 8714965. PMID 34977038.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  9. ^ Feng, Xinghua; Liu, Siyu; Xu, Haoxing (5 June 2023). "Not just protons: Chloride also activates lysosomal acidic hydrolases". The Journal of Cell Biology. 222 (6): e202305007. doi:10.1083/jcb.202305007. ISSN 1540-8140. PMC 10191866. PMID 37191899.
  10. ^ Brouillette, Monique (1 December 2016). "Biology 101 Update: A Cell's Lysosomes Are More Than Garbage Disposals". Scientific American. Retrieved 9 April 2025.
  11. ^ Brouillette, Monique (1 December 2016). "Biology 101 Update: A Cell's Lysosomes Are More Than Garbage Disposals". Scientific American. Retrieved 9 April 2025.
  12. ^ Feng, Xinghua; Liu, Siyu; Xu, Haoxing (5 June 2023). "Not just protons: Chloride also activates lysosomal acidic hydrolases". The Journal of Cell Biology. 222 (6): e202305007. doi:10.1083/jcb.202305007. ISSN 1540-8140. PMC 10191866. PMID 37191899.
  13. ^ Mindell, Joseph A. (17 March 2012). "Lysosomal Acidification Mechanisms*". Annual Review of Physiology. 74: 69–86. doi:10.1146/annurev-physiol-012110-142317. ISSN 0066-4278.
  14. ^ Ishida, Yoichi; Nayak, Smita; Mindell, Joseph A.; Grabe, Michael (27 May 2013). "A model of lysosomal pH regulation". Journal of General Physiology. 141 (6): 705–720. doi:10.1085/jgp.201210930. ISSN 0022-1295. PMC 3664703. PMID 23712550.
  15. ^ a b c d Platt, Frances M.; Boland, Barry; van der Spoel, Aarnoud C. (26 November 2012). "Lysosomal storage disorders: The cellular impact of lysosomal dysfunction". Journal of Cell Biology. 199 (5): 723–734. doi:10.1083/jcb.201208152. ISSN 0021-9525. PMC 3514785. PMID 23185029.
  16. ^ a b c d e Samie, Mohammad Ali; Xu, Haoxing (1 June 2014). "Lysosomal exocytosis and lipid storage disorders". Journal of Lipid Research. 55 (6): 995–1009. doi:10.1194/jlr.R046896. ISSN 0022-2275. PMC 4031951. PMID 24668941.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  17. ^ Coutinho, Maria Francisca; Prata, Maria João; Alves, Sandra (1 April 2012). "Mannose-6-phosphate pathway: A review on its role in lysosomal function and dysfunction". Molecular Genetics and Metabolism. 105 (4): 542–550. doi:10.1016/j.ymgme.2011.12.012. ISSN 1096-7192.
  18. ^ Coutinho, Maria Francisca; Prata, Maria João; Alves, Sandra (1 April 2012). "Mannose-6-phosphate pathway: A review on its role in lysosomal function and dysfunction". Molecular Genetics and Metabolism. 105 (4): 542–550. doi:10.1016/j.ymgme.2011.12.012. ISSN 1096-7192.
  19. ^ Luzio, J. Paul; Hackmann, Yvonne; Dieckmann, Nele M. G.; Griffiths, Gillian M. (2 September 2014). "The biogenesis of lysosomes and lysosome-related organelles". Cold Spring Harbor Perspectives in Biology. 6 (9): a016840. doi:10.1101/cshperspect.a016840. ISSN 1943-0264. PMC 4142962. PMID 25183830.
  20. ^ Nguyen, Jenny A.; Yates, Robin M. (2021). "Better Together: Current Insights Into Phagosome-Lysosome Fusion". Frontiers in Immunology. 12: 636078. doi:10.3389/fimmu.2021.636078. ISSN 1664-3224. PMC 7946854. PMID 33717183.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  21. ^ Kaur, Gulpreet; Lakkaraju, Aparna (2018). "Early Endosome Morphology in Health and Disease". Advances in Experimental Medicine and Biology. 1074: 335–343. doi:10.1007/978-3-319-75402-4_41. ISSN 0065-2598. PMC 6563932. PMID 29721961.
  22. ^ Kaur, Gulpreet; Lakkaraju, Aparna (2018). "Early Endosome Morphology in Health and Disease". Advances in Experimental Medicine and Biology. 1074: 335–343. doi:10.1007/978-3-319-75402-4_41. ISSN 0065-2598. PMC 6563932. PMID 29721961.
  23. ^ Bird, Lauren E; Edgington-Mitchell, Laura E; Newton, Hayley J (1 August 2023). "Eat, prey, love: Pathogen-mediated subversion of lysosomal biology". Current Opinion in Immunology. 83: 102344. doi:10.1016/j.coi.2023.102344. ISSN 0952-7915.
  24. ^ Sabatini, David D.; Adesnik, Milton (13 August 2013). "Christian de Duve: Explorer of the cell who discovered new organelles by using a centrifuge". Proceedings of the National Academy of Sciences of the United States of America. 110 (33): 13234–13235. doi:10.1073/pnas.1312084110. ISSN 1091-6490. PMC 3746853. PMID 23924611.
  25. ^ Bird, Lauren E; Edgington-Mitchell, Laura E; Newton, Hayley J (1 August 2023). "Eat, prey, love: Pathogen-mediated subversion of lysosomal biology". Current Opinion in Immunology. 83: 102344. doi:10.1016/j.coi.2023.102344. ISSN 0952-7915.
  26. ^ "In brief: The innate and adaptive immune systems", InformedHealth.org [Internet], Institute for Quality and Efficiency in Health Care (IQWiG), 14 August 2023, retrieved 9 April 2025
  27. ^ "In brief: The innate and adaptive immune systems", InformedHealth.org [Internet], Institute for Quality and Efficiency in Health Care (IQWiG), 14 August 2023, retrieved 9 April 2025
  28. ^ Sabatini, David D.; Adesnik, Milton (13 August 2013). "Christian de Duve: Explorer of the cell who discovered new organelles by using a centrifuge". Proceedings of the National Academy of Sciences of the United States of America. 110 (33): 13234–13235. doi:10.1073/pnas.1312084110. ISSN 1091-6490. PMC 3746853. PMID 23924611.
  29. ^ Wei, Bangdong L.; Denton, Paul W.; O'Neill, Eduardo; Luo, Tianci; Foster, John L.; Garcia, J. Victor (May 2005-05). "Inhibition of Lysosome and Proteasome Function Enhances Human Immunodeficiency Virus Type 1 Infection". Journal of Virology. 79 (9): 5705–5712. doi:10.1128/jvi.79.9.5705-5712.2005. PMC 1082736. PMID 15827185. {{cite journal}}: Check date values in: |date= (help)
  30. ^ Samie, Mohammad Ali; Xu, Haoxing (1 June 2014). "Lysosomal exocytosis and lipid storage disorders". Journal of Lipid Research. 55 (6): 995–1009. doi:10.1194/jlr.R046896. ISSN 0022-2275. PMC 4031951. PMID 24668941.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  31. ^ a b c d Platt, Frances M.; Boland, Barry; van der Spoel, Aarnoud C. (26 November 2012). "Lysosomal storage disorders: The cellular impact of lysosomal dysfunction". Journal of Cell Biology. 199 (5): 723–734. doi:10.1083/jcb.201208152. ISSN 0021-9525. PMC 3514785. PMID 23185029.
  32. ^ Carmona-Gutierrez, Didac; Hughes, Adam L.; Madeo, Frank; Ruckenstuhl, Christoph (1 December 2016). "The crucial impact of lysosomes in aging and longevity". Ageing Research Reviews. Lysosomes in Aging. 32: 2–12. doi:10.1016/j.arr.2016.04.009. ISSN 1568-1637. PMC 5081277. PMID 27125853.
  33. ^ Bouhamdani, Nadia; Comeau, Dominique; Turcotte, Sandra (15 December 2021). "A Compendium of Information on the Lysosome". Frontiers in Cell and Developmental Biology. 9. doi:10.3389/fcell.2021.798262. ISSN 2296-634X.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  34. ^ Samie, Mohammad Ali; Xu, Haoxing (1 June 2014). "Lysosomal exocytosis and lipid storage disorders". Journal of Lipid Research. 55 (6): 995–1009. doi:10.1194/jlr.R046896. ISSN 0022-2275. PMC 4031951. PMID 24668941.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  35. ^ Carmona-Gutierrez, Didac; Hughes, Adam L.; Madeo, Frank; Ruckenstuhl, Christoph (1 December 2016). "The crucial impact of lysosomes in aging and longevity". Ageing Research Reviews. Lysosomes in Aging. 32: 2–12. doi:10.1016/j.arr.2016.04.009. ISSN 1568-1637. PMC 5081277. PMID 27125853.
  36. ^ De Duve, Christian; De Barsy, Thierry; Poole, Brian; Trouet, Andre´; Tulkens, Paul; Van Hoof, Fran¸ois (15 September 1974). "Lysosomotropic agents". Biochemical Pharmacology. 23 (18): 2495–2531. doi:10.1016/0006-2952(74)90174-9. ISSN 0006-2952.
  37. ^ Traganos, Frank; Darzynkiewicz, Zbigniew (1 January 1994), Darzynkiewicz, Zbigniew; Paul Robinson, J.; Crissman, Harry A. (eds.), "Chapter 12 Lysosomal Proton Pump Activity: Supravital Cell Staining with Acridine Orange Differentiates Leukocyte Subpopulations", Methods in Cell Biology, Flow Cytometry Second Edition, Part A, vol. 41, Academic Press, pp. 185–194, doi:10.1016/s0091-679x(08)61717-3, retrieved 9 April 2025
  38. ^ Trapp, Stefan; Rosania, Gus R.; Horobin, Richard W.; Kornhuber, Johannes (1 October 2008). "Quantitative modeling of selective lysosomal targeting for drug design". European Biophysics Journal. 37 (8): 1317–1328. doi:10.1007/s00249-008-0338-4. ISSN 1432-1017. PMC 2711917. PMID 18504571.
  39. ^ Kornhuber, Johannes; Schultz, Andreas; Wiltfang, Jens; Meineke, Ingolf; Gleiter, Christoph H.; Zöchling, Robert; Boissl, Karl-Werner; Leblhuber, Friedrich; Riederer, Peter (June 1999). "Persistence of Haloperidol in Human Brain Tissue". American Journal of Psychiatry. 156 (6): 885–890. doi:10.1176/ajp.156.6.885. ISSN 0002-953X.
  40. ^ Kornhuber, J.; Weigmann, H.; Röhrich, J.; Wiltfang, J.; Bleich, S.; Meineke, I.; Zöchling, R.; Härtter, S.; Riederer, P.; Hiemke, C. (1 March 2006). "Region specific distribution of levomepromazine in the human brain". Journal of Neural Transmission. 113 (3): 387–397. doi:10.1007/s00702-005-0331-3. ISSN 1435-1463.
  41. ^ Kornhuber, J.; Quack, G.; Danysz, W.; Jellinger, K.; Danielczyk, W.; Gsell, W.; Riederer, P. (1 July 1995). "Therapeutic brain concentration of the NMDA receptor antagonist amantadine". Neuropharmacology. 34 (7): 713–721. doi:10.1016/0028-3908(95)00056-C. ISSN 0028-3908.
  42. ^ Kornhuber, Johannes; Tripal, Philipp; Reichel, Martin; Terfloth, Lothar; Bleich, Stefan; Wiltfang, Jens; Gulbins, Erich (1 January 2008). "Identification of New Functional Inhibitors of Acid Sphingomyelinase Using a Structure−Property−Activity Relation Model". Journal of Medicinal Chemistry. 51 (2): 219–237. doi:10.1021/jm070524a. ISSN 0022-2623.
  43. ^ Kornhuber, Johannes; Muehlbacher, Markus; Trapp, Stefan; Pechmann, Stefanie; Friedl, Astrid; Reichel, Martin; Mühle, Christiane; Terfloth, Lothar; Groemer, Teja W.; Spitzer, Gudrun M.; Liedl, Klaus R.; Gulbins, Erich; Tripal, Philipp (31 August 2011). "Identification of Novel Functional Inhibitors of Acid Sphingomyelinase". PLOS ONE. 6 (8): e23852. doi:10.1371/journal.pone.0023852. ISSN 1932-6203. PMC 3166082. PMID 21909365.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  44. ^ Marshall, Kirsty; Easton, Chris (25 July 2018). "The role of asset-based approaches in community nursing". Primary Health Care. 28 (5). doi:10.7748/phc.2018.e1339. ISSN 0264-5033.
  45. ^ Albin, Roger L.; Dauer, William T. (1 May 2014). "Magic shotgun for Parkinson's disease?". Brain. 137 (5): 1274–1275. doi:10.1093/brain/awu076. ISSN 0006-8950.
  46. ^ McNeill, Alisdair; Magalhaes, Joana; Shen, Chengguo; Chau, Kai-Yin; Hughes, Derralyn; Mehta, Atul; Foltynie, Tom; Cooper, J. Mark; Abramov, Andrey Y.; Gegg, Matthew; Schapira, Anthony H. V. (May 2014). "Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells". Brain: A Journal of Neurology. 137 (Pt 5): 1481–1495. doi:10.1093/brain/awu020. ISSN 1460-2156. PMC 3999713. PMID 24574503.
  47. ^ "Lupus: Symptoms & Treatment". web.archive.org. 3 April 2025. Retrieved 9 April 2025.
  48. ^ Hakkim, Abdul; Fürnrohr, Barbara G.; Amann, Kerstin; Laube, Britta; Abed, Ulrike Abu; Brinkmann, Volker; Herrmann, Martin; Voll, Reinhard E.; Zychlinsky, Arturo (25 May 2010). "Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis". Proceedings of the National Academy of Sciences. 107 (21): 9813–9818. doi:10.1073/pnas.0909927107. PMC 2906830. PMID 20439745.
  49. ^ a b Monteith, Andrew J.; Kang, SunAh; Scott, Eric; Hillman, Kai; Rajfur, Zenon; Jacobson, Ken; Costello, M. Joseph; Vilen, Barbara J. (12 April 2016). "Defects in lysosomal maturation facilitate the activation of innate sensors in systemic lupus erythematosus". Proceedings of the National Academy of Sciences. 113 (15): E2142 – E2151. doi:10.1073/pnas.1513943113. PMC 4839468. PMID 27035940.
  50. ^ Kavai, Maria; Szegedi, Gyula (1 August 2007). "Immune complex clearance by monocytes and macrophages in systemic lupus erythematosus". Autoimmunity Reviews. 6 (7): 497–502. doi:10.1016/j.autrev.2007.01.017. ISSN 1568-9972.
  51. ^ Kávai, M.; Csipö, I.; Sonkoly, J.; Csongor, J.; Szegedi, G. Y. (1986). "Defective Immune Complex Degradation by Monocytes in Patients with Systemic Lupus Erythematosus". Scandinavian Journal of Immunology. 24 (5): 527–532. doi:10.1111/j.1365-3083.1986.tb02167.x. ISSN 1365-3083.
  52. ^ Monteith, Andrew J; Vincent, Heather A; Kang, SunAh; Li, Patrick; Claiborne, Tauris M; Rajfur, Zenon; Jacobson, Ken; Moorman, Nathaniel J; Vilen, Barbara J (1 July 2018). "mTORC2 Activity Disrupts Lysosome Acidification in Systemic Lupus Erythematosus by Impairing Caspase-1 Cleavage of Rab39a". The Journal of Immunology. 201 (2): 371–382. doi:10.4049/jimmunol.1701712. ISSN 0022-1767. PMC 6039264. PMID 29866702.
  53. ^ Kang, SunAh; Rogers, Jennifer L; Monteith, Andrew J; Jiang, Chuancang; Schmitz, John; Clarke, Stephen H; Tarrant, Teresa K; Truong, Young K; Diaz, Marilyn; Fedoriw, Yuri; Vilen, Barbara J (1 May 2016). "Apoptotic Debris Accumulates on Hematopoietic Cells and Promotes Disease in Murine and Human Systemic Lupus Erythematosus". The Journal of Immunology. 196 (10): 4030–4039. doi:10.4049/jimmunol.1500418. ISSN 0022-1767. PMC 4868781. PMID 27059595.
  54. ^ Kang, SunAh; Fedoriw, Yuri; Brenneman, Ethan K; Truong, Young K; Kikly, Kristine; Vilen, Barbara J (1 April 2017). "BAFF Induces Tertiary Lymphoid Structures and Positions T Cells within the Glomeruli during Lupus Nephritis". The Journal of Immunology. 198 (7): 2602–2611. doi:10.4049/jimmunol.1600281. ISSN 0022-1767. PMC 5360485. PMID 28235864.
  55. ^ "Lysosome Enzyme - an overview | ScienceDirect Topics". www.sciencedirect.com. Retrieved 9 April 2025.
  56. ^ "Nuclease - an overview | ScienceDirect Topics". www.sciencedirect.com. Retrieved 9 April 2025.
  57. ^ "Glycosidase - an overview | ScienceDirect Topics". www.sciencedirect.com. Retrieved 9 April 2025.
  58. ^ "Lipase - an overview | ScienceDirect Topics". www.sciencedirect.com. Retrieved 9 April 2025.
  59. ^ "Phospholipase - an overview | ScienceDirect Topics". www.sciencedirect.com. Retrieved 9 April 2025.
  60. ^ "Phosphatase - an overview | ScienceDirect Topics". www.sciencedirect.com. Retrieved 9 April 2025.
  61. ^ "Sulfatase - an overview | ScienceDirect Topics". www.sciencedirect.com. Retrieved 9 April 2025.
[edit]
Look up lysosome in Wiktionary, the free dictionary.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Lysosome&oldid=1284790942"